Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1475-2840
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure ; volume:19 ; number:1 ; day:30 ; month:9 ; year:2020 ; pages:1-16 ; date:12.2020
Cardiovascular diabetology ; 19, Heft 1 (30.9.2020), 1-16, 12.2020

Creator
Sayour, Alex Ali
Oláh, Attila
Ruppert, Mihály
Barta, Bálint András
Horváth, Eszter Mária
Benke, Kálmán
Pólos, Miklós
Hartyánszky, István
Merkely, Béla
Radovits, Tamás
Contributor
SpringerLink (Online service)

DOI
10.1186/s12933-020-01141-1
URN
urn:nbn:de:101:1-2020111514380943520040
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Sayour, Alex Ali
  • Oláh, Attila
  • Ruppert, Mihály
  • Barta, Bálint András
  • Horváth, Eszter Mária
  • Benke, Kálmán
  • Pólos, Miklós
  • Hartyánszky, István
  • Merkely, Béla
  • Radovits, Tamás
  • SpringerLink (Online service)

Other Objects (12)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review

Sodium-glucose co-transporter 2 inhibitors in left ventricular assist device and heart transplant recipients: a mini-review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Related objects